Previous 10 | Next 10 |
2023-11-13 08:49:46 ET More on Reneo Pharmaceuticals Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop HC Wainwright starts Reneo at buy, sees possible 2025 launch for lead drug Seeking Alpha’s Quant Rating on Reneo Pharmaceuticals Historica...
IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third...
2023-10-29 20:00:00 ET Summary Reneo Pharmaceuticals is developing mitochondrial disease therapies, with its lead program being mavodelpar or REN001. Mavodelpar has shown promising results in increasing fatty acid oxidation and improving muscle strength in clinical trials. The...
IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the company will present a pos...
IRVINE, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced last patient last visit (LPLV) in th...
IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s mana...
2023-08-28 13:58:10 ET HC Wainwright started coverage of Reneo Pharmaceuticals ( NASDAQ: RPHM ) with a buy rating, citing the prospects of its lead drug mavodelpar in the treatment of primary mitochondrial myopathies, or PMM. The investment bank said it sees a “very low b...
2023-08-28 10:05:32 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...
2023-08-10 12:12:57 ET Reneo Pharmaceuticals press release ( NASDAQ: RPHM ): Q2 GAAP EPS of -$0.65 misses by $0.13 . $142.7 million in cash, cash equivalents, and short-term investments as of June 30, 2023. For further details see: Reneo Pharmaceuticals GAAP ...
IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the secon...
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...